An observational study in Kidney Neoplasm and Renal Mass up to 7cm, sponsored by University of Leipzig. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by University of Leipzig · Observational
The goal of this prospective observational study is to learn about the use of a novel imaging technique called hyperspectral imaging in adult participants who are having surgery for removing a tumor from their kidney. Hyperspectral imaging works by shining light on a structure (in this case, the kidney tissue with the tumor) and capturing how it reflects hundreds of very narrow color bands, including ones the human eye can't see. These patterns depend on the composition of the tissue and for example how well blood is flowing through the tissue. By studying these patterns, the investigators want to understand if this technique can be helpful for the surgery where only the part of the kidney with the tumor is removed.
The main questions it aims to answer are:
The imaging will happen during the already planned surgery and the participant does not need to undergo any additional tests.
969 studies on the registry are indexed under Kidney Neoplasms; 210 are open to participants now.
This study's planned enrollment of 60 is below the median of 211 across 215 observational studies indexed under Kidney Neoplasms.
Browse Kidney Neoplasms studies →University of Leipzig is the lead sponsor of 148 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Eligible participants for the trial will be selected from all patients referred to the Department of Urology at the University Hospital Leipzig for undergoing partial nephrectomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Correlation of hyperspectral imaging (HSI) data with clamping technique during robot-assisted partial nephrectomy (RAPN)
Time frame: day of surgery
Correlation of HSI data with histopathological report
Time frame: day of surgery
Correlation of HSI data with demographic parameters
Time frame: day of surgery
Correlation of HSI data and respective clamping technique with postoperative kidney function
Time frame: from the day of surgery until discharge (up to 6 days)
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.